NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.75% | 57.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.67% | 31.61% | |||
| Operating Income | 4.67% | -31.61% | |||
| Income Before Tax | 4.70% | -26.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.70% | -26.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.70% | -26.59% | |||
| EBIT | 4.67% | -31.61% | |||
| EBITDA | 5.00% | -29.75% | |||
| EPS Basic | 6.19% | -21.25% | |||
| Normalized Basic EPS | 5.79% | -21.00% | |||
| EPS Diluted | 6.19% | -21.25% | |||
| Normalized Diluted EPS | 5.79% | -21.00% | |||
| Average Basic Shares Outstanding | 1.37% | 4.28% | |||
| Average Diluted Shares Outstanding | 1.37% | 4.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||